Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
Executive Summary
Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)
You may also be interested in...
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
The APACHE II sepsis score is the most appropriate tool to estimate the likelihood of a Xigris benefit in a particular patient, labeling for Lilly's biologic states
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
The APACHE II sepsis score is the most appropriate tool to estimate the likelihood of a Xigris benefit in a particular patient, labeling for Lilly's biologic states
Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA
Lilly's sepsis agent Xigris will be priced at an average net wholesale price of $6,800 per 96-hour course of therapy, depending on the weight of the patient